Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Mar 16, 2021 8:59pm
127 Views
Post# 32813792

RE:RE:RE:RE:Hard belly fat

RE:RE:RE:RE:Hard belly fatRemember, they rent lab space at UQAM, the university where Dr. Beliveau is a professor. So they are already in a place where they have personnel to take care of the animal part of the whole research process, so if they need to hire a full time employee dedicated to that for them, it means that they are doing some intensive animal testing and they are planning to do that in the future. If early phase I is positive, they will have a lot of work because the combination of peptides, linkers and drugs are numerous.

SPCEO1 wrote: Now, I have to think the animal testing for TH-1902 is completed. So, one wonders what they migth be planning to test goign forward. We have no idea what they have been up to in the labs and what progress they may have been making on new versions of the drug (TH-1906 perhaps). But if they are committing to hiring someone like this, rather than farming it out to a consultant, that would seemingly indicate there may be more going on than we are presently aware of. Hopefully, they are coming up with some really interesting things as they work to understand more about PDC's. 

jfm1330 wrote: On the french version of the career page they are looking to hire a laboratory animal technician dedicated to cancer research. To hire a ful time tech for that purpose means they are working intensively on animal testing. So maybe we will see more stuff on that front.


scarlet1967 wrote:
https://www.theratech.com/career/

 

 




<< Previous
Bullboard Posts
Next >>